Lantheus Medical Imaging said today that it plans to offer some 9.3 million shares of stock in an initial public offering that could bring in as much as $139 million.
Billerica, Mass.-based Lantheus said it plans to price the offering at $12 to $15 per share, for a range of $111.1 million to $138.9 million.
At the midpoint of the proposed range, Lantheus would command a fully diluted market capitalization of $370 million.
Lantheus, which makes imaging agents and other diagnostic products, deals primarily in radiopharmaceutical and contrast agents, according to its IPO prospectus.
Lantheus hopes to use the funds to redeem a portion of its outstanding senior notes due in 2017, planning to reserve the rest for "general corporate purposes." Lantheus plans to trade on the NASDAQ market under the symbol LNTH.
In March, Lantheus exited a federal tax evasion row when it agreed to pay $6.2 million to settle allegations that the company and former parent Bristol-Myers Squibb schemed to avoid paying sales taxes.